Xiao Cheng, Yu Miao, Liu Jieying, Wu Han, Deng Mingqun, Zhang Qian, Xiao Xinhua
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Stem Cell Res. 2020 Apr;44:101753. doi: 10.1016/j.scr.2020.101753. Epub 2020 Mar 14.
Familial partial lipodystrophy type 2 (FPLD2) is a rare autosomal dominant metabolic disorder caused by heterozygous mutations in the LMNA gene, which encodes for the lamin A/C. Although multiple mutations have been reported in FPLD2 patients, the mechanism remains unclear due to the lack of cellular models for the disease. We previously have generated an iPSC line (PUMCHi001-A) from a FPLD2 patient with a heterozygous R349W mutation in the LMNA gene. Here we genetically corrected the R349W mutation in the LMNA gene using CRISPR/Cas9 technology to generate an isogenic control, which was an ideal control to exclude differences in genetic background between individuals while investigating the pathogenesis of the mutation in the disease.
2型家族性部分脂肪营养不良(FPLD2)是一种罕见的常染色体显性代谢紊乱疾病,由LMNA基因突变引起,该基因编码核纤层蛋白A/C。尽管在FPLD2患者中已报道了多种突变,但由于缺乏该疾病的细胞模型,其发病机制仍不清楚。我们之前从一名LMNA基因存在杂合R349W突变的FPLD2患者中生成了一个诱导多能干细胞系(PUMCHi001-A)。在此,我们使用CRISPR/Cas9技术对LMNA基因中的R349W突变进行基因校正,以生成一个同基因对照,这是在研究该疾病突变的发病机制时排除个体间遗传背景差异的理想对照。